Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives $3.94 Consensus PT from Brokerages

Shares of Lucid Diagnostics Inc. (NASDAQ:LUCD) have been assigned an average recommendation of “Moderate Buy” from the five ratings firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $3.9375.

A number of research analysts have commented on the stock. Ascendiant Capital Markets increased their price objective on shares of Lucid Diagnostics from $8.00 to $8.25 and gave the company a “buy” rating in a research note on Wednesday, December 10th. Wall Street Zen downgraded shares of Lucid Diagnostics from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Lucid Diagnostics in a research note on Monday, December 29th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $3.00 price target on shares of Lucid Diagnostics in a research note on Thursday.

Key Headlines Impacting Lucid Diagnostics

Here are the key news stories impacting Lucid Diagnostics this week:

• Positive Sentiment: Company signaled expanded U.S. Department of Veterans Affairs market access and reported 29% sequential test-volume growth while management said it is targeting Medicare and commercial payer wins — a clear commercialization catalyst if reimbursement gains follow. Lucid Diagnostics signals expanded VA market access and 29% sequential test volume growth
• Positive Sentiment: Needham & Company reaffirmed a Buy rating and set a $3.00 price target, implying substantial upside from current levels — analyst support can boost investor confidence and trading interest. Benzinga
• Positive Sentiment: Company reported Q4 operational progress: processed 3,664 EsoGuard tests, recognized $1.5M in revenue, and highlighted positive real‑world data from esophageal precancer detection — evidence that commercial adoption and clinical validation are advancing. Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Management commentary and the full earnings-call/transcript provide additional color on commercialization priorities, payer strategy and next milestones; useful for gauging timeline risk but not an immediate price driver on its own. Q4 2025 Earnings Call Transcript Earnings Transcript (Yahoo)
• Neutral Sentiment: Third‑party summaries note revenue outpaced consensus (about $1.5M) and the company increased cash to roughly $34.7M, but institutional holdings show mixed buying and large position changes — signals of both interest and repositioning by larger holders. QuiverQuant: Stock Rises on Q4 2025 Earnings
• Negative Sentiment: Profitability remains a concern: Lucid reported a $0.10 per-share loss in Q4, which was worse than one estimate and highlights ongoing operating losses and negative cash flow — key risks if revenue and reimbursement progress don’t accelerate. Zacks: Reports Q4 Loss, Beats Revenue Estimates

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Centiva Capital LP bought a new stake in shares of Lucid Diagnostics in the 3rd quarter valued at approximately $25,000. Sprott Inc. bought a new position in Lucid Diagnostics during the third quarter worth $25,000. SG Americas Securities LLC acquired a new position in Lucid Diagnostics in the third quarter worth $26,000. Quadrature Capital Ltd acquired a new position in Lucid Diagnostics in the second quarter worth $29,000. Finally, Abel Hall LLC bought a new stake in Lucid Diagnostics during the fourth quarter valued at $33,000. Institutional investors own 74.01% of the company’s stock.

Lucid Diagnostics Trading Down 3.4%

Lucid Diagnostics stock opened at $1.15 on Tuesday. The stock has a market cap of $158.33 million, a P/E ratio of -1.11 and a beta of 1.18. The stock has a 50 day moving average of $1.30 and a 200-day moving average of $1.18. Lucid Diagnostics has a 52 week low of $0.95 and a 52 week high of $1.80.

Lucid Diagnostics (NASDAQ:LUCD) last issued its quarterly earnings results on Thursday, March 26th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.03). The company had revenue of $1.50 million for the quarter, compared to analyst estimates of $1.39 million. As a group, equities analysts predict that Lucid Diagnostics will post -0.84 earnings per share for the current fiscal year.

About Lucid Diagnostics

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.